GET DAILY SIGNALSWhy Is WW International (WW) Stock Down -5.37% Today?
Key Takeaways
- WW shares fell roughly 5.37% intraday, trading near $12.15 versus a prior close of $12.84.
- The primary catalyst was a post-earnings reaction: strong bottom-line results were overshadowed by declining revenue and a weaker-than-expected full-year sales outlook.
- Secondary drivers included a shrinking behavioral subscriber base, a sequential decline in clinical subscribers, and a narrowed 2026 revenue guidance range that came in below consensus.
- New CEO Stephen Bye acknowledged the company is "falling short of its potential" while targeting a return to sustainable, profitable growth in 2027.
- Traders are watching the upcoming fourth-quarter peak season, marketing spend, and the company's continued pivot toward GLP-1-related offerings.
- For more detail on this ticker, explore its Price Targets, Earnings, and Forecast pages.
- You can also discover AI-driven trading strategies by exploring the Trending AI Robots section.
Opening Summary
WW International, Inc. (NASDAQ: WW), better known as Weight Watchers, is a global weight-management company that combines science-backed behavioral programs, clinical care, and access to GLP-1 medications. In Friday's session, WW shares fell approximately 5.37% to trade near $12.15, down from a prior close of $12.84. The decline extended a negative reaction to the company's third-quarter 2026 results, which beat on earnings but revealed ongoing top-line contraction and a full-year revenue outlook that fell short of Wall Street's expectations.
Earnings Beat Overshadowed by Revenue Declines
The central tension in the quarter was a strong profit result paired with a shrinking business. WW reported earnings of $1.51 per share, far above analyst estimates, and swung to a net income of $15.1 million from a $57.5 million loss a year earlier. Adjusted EBITDA rose 21% to $51.7 million, with margins expanding to 33.8%. Much of that improvement, however, reflected cost discipline and sharply lower marketing spend rather than sales growth.
Revenue fell 11.2% year over year to $152.9 million, driven by a 22% drop in behavioral subscription revenue. Behavioral subscribers declined 26% to roughly 2.1 million. While clinical subscription revenue jumped 48% to $38 million and Core+ subscribers grew 16%, the overall subscriber base continued to shrink, and clinical subscribers declined sequentially from 197,000 to 174,000.
Weaker Guidance Weighs on Sentiment
Guidance compounded investor concerns. The company narrowed its 2026 revenue forecast to $625 million–$630 million, a range whose ceiling was lowered and which sat below the consensus estimate near $630.8 million. Although the adjusted EBITDA range was raised at the low end to $110 million–$115 million, the revenue signal suggested the company has not yet stabilized its top line. The market reaction reflected a "beat the bottom line, miss the outlook" dynamic, with the softer sales trajectory overshadowing the profitability gains.
New CEO Flags a Turnaround That Is Still Ahead
Adding to the narrative, newly appointed CEO Stephen Bye said during the earnings call that the company is "falling short of its potential" and emphasized a focus on strengthening the member experience and improving products. Bye framed 2027 as the year the company aims to restore sustainable, profitable growth, pointing to opportunities in the expanding GLP-1 medication market, including the Medicare GLP-1 Bridge Program. While the strategic direction was well received in concept, the lack of immediate revenue acceleration left investors cautious.
Market Context and Trading Activity
The move in WW was fundamentally earnings-driven rather than a reflection of broad market weakness. Trading volume was elevated relative to recent sessions as investors repriced the stock following the report, continuing the volatile range the shares have traded in around the earnings event. The decline reflected company-specific fundamentals—declining subscribers and a muted revenue outlook—more than sector momentum, underscoring that the stock's path remains tied to its ability to convert a profitable, leaner model into renewed growth.
What Comes Next for WW
Looking ahead, investors will focus on the fourth quarter, which includes the company's seasonal peak and a planned step-up in marketing spend as it prepares for 2027. Key watch items include whether Core+ and clinical revenue can offset ongoing behavioral-subscriber declines, how the GLP-1-related offerings perform, and whether the new leadership team can translate strategic ambitions into measurable subscriber and revenue stabilization. Risks remain substantial: continued erosion of the core behavioral base, competitive pressure in the weight-management and GLP-1 space, and execution risk around the 2027 turnaround timeline.
Trending AI Robots
Tickeron's Trending AI Robots page showcases a curated selection of AI-powered trading bots that are performing strongly under current market conditions. Tickeron offers hundreds of AI trading bots covering thousands of tickers, but only the top performers make it into this featured section. These bots vary by strategy, timeframe, performance metrics, and the symbols they trade, giving traders a range of approaches to explore. If you are interested in data-driven trading ideas, consider visiting the Trending AI Robots page to review the latest standout strategies.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Momentum Indicator for WW turns negative, indicating new downward trend
WW saw its Momentum Indicator move below the 0 level on November 03, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 89 similar instances where the indicator turned negative. In 82 of the 89 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Moving Average Convergence Divergence Histogram (MACD) for WW turned negative on November 04, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 44 similar instances when the indicator turned negative. In 39 of the 44 cases the stock turned lower in the days that followed. This puts the odds of success at 89%.
WW moved below its 50-day moving average on October 07, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for WW crossed bearishly below the 50-day moving average on October 01, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 14 of 15 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where WW declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for WW entered a downward trend on November 05, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
Following a +9.85% 3-day Advance, the price is estimated to grow further. Considering data from situations where WW advanced for three days, in 212 of 254 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
WW may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is 11 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 64 (best 1 - 100 worst), indicating fairly steady price growth. WW’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 84 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.461) is normal, around the industry mean (203.977). P/E Ratio (0.939) is within average values for comparable stocks, (20.904). Projected Growth (PEG Ratio) (5.307) is also within normal values, averaging (2.498). Dividend Yield (0.000) settles around the average of (0.097) among similar stocks. P/S Ratio (0.167) is also within normal values, averaging (2.688).
The Tickeron PE Growth Rating for this company is 94 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. WW’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 82, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a provider of weight management services
Industry HospitalNursingManagement
Advertisement